M Balzer-Geldsetzer1, J Klotsche2, R Dodel1,3, O Riedel4. 1. Geriatric Centre Haus Berge, Contilia GmbH, University Hospital Essen, Essen, Germany. 2. Deutsches Rheumaforschungszentrum-ein Leibniz Institut, Berlin, Germany. 3. Department of Neurology, Phillips University Marburg, Marburg, Germany. 4. Leibniz Institute for Prevention Research and Epidemiology-BIPS, Achterstrasse 30, 28359, Bremen, Germany. riedel@leibniz-bips.de.
Abstract
BACKGROUND: Parkinson's disease (PD) is characterized by severe motor and non-motor symptoms reducing patients' quality of life (QoL). Instruments have been well established for QoL assessments in PD, including the EuroQol (EQ-5D), the Parkinson's disease questionnaire (PDQ-39), or rather uncommon, like the WHOQOL-100. So far, the impact of variables has been investigated for each of these measures separately in different study populations, limiting the comparability of the results. Thus, this study compared the EQ-5D, PDQ-39, and the WHOQOL-100 (with its short-form WHOQOL-BREF) in the same study population. METHODS: Seventy-five PD outpatients were assessed in a prospective study, including disease severity according to Hoehn and Yahr stage (HY) and Unified Parkinson Disease Rating Scale (UPDRS). The Geriatric Depression Scale (GDS-15) screened for depression. RESULTS: Decreased QoL was found with all three instruments. In multivariate models, sex and treatment complications had an impact on QoL according to all three measures, while duration of PD and HY was not associated with QoL in any of them. Depression was relevant for the WHOQOL-100/WHOQOL-BREF and the PDQ-39, but not for the EQ-5D. The total variances explained by the WHOQOL-100, WHOQOL-BREF, PDQ-39, and the EQ-5D were 0.27, 0.34, 0.70, and 0.50, respectively. CONCLUSIONS: The associations between clinical aspects of PD and QoL vary substantially among all three measures. Importantly, depression as a frequent comorbidity in PD is underestimated by the EQ-5D, but not by the PDQ-39 and the WHOQOL-100/WHOQOL-BREF. In turn, motor impairments are underestimated by the latter and associated strongest with QoL in the EQ-5D.
BACKGROUND:Parkinson's disease (PD) is characterized by severe motor and non-motor symptoms reducing patients' quality of life (QoL). Instruments have been well established for QoL assessments in PD, including the EuroQol (EQ-5D), the Parkinson's disease questionnaire (PDQ-39), or rather uncommon, like the WHOQOL-100. So far, the impact of variables has been investigated for each of these measures separately in different study populations, limiting the comparability of the results. Thus, this study compared the EQ-5D, PDQ-39, and the WHOQOL-100 (with its short-form WHOQOL-BREF) in the same study population. METHODS: Seventy-five PD outpatients were assessed in a prospective study, including disease severity according to Hoehn and Yahr stage (HY) and Unified Parkinson Disease Rating Scale (UPDRS). The Geriatric Depression Scale (GDS-15) screened for depression. RESULTS: Decreased QoL was found with all three instruments. In multivariate models, sex and treatment complications had an impact on QoL according to all three measures, while duration of PD and HY was not associated with QoL in any of them. Depression was relevant for the WHOQOL-100/WHOQOL-BREF and the PDQ-39, but not for the EQ-5D. The total variances explained by the WHOQOL-100, WHOQOL-BREF, PDQ-39, and the EQ-5D were 0.27, 0.34, 0.70, and 0.50, respectively. CONCLUSIONS: The associations between clinical aspects of PD and QoL vary substantially among all three measures. Importantly, depression as a frequent comorbidity in PD is underestimated by the EQ-5D, but not by the PDQ-39 and the WHOQOL-100/WHOQOL-BREF. In turn, motor impairments are underestimated by the latter and associated strongest with QoL in the EQ-5D.
Authors: Monika Balzer-Geldsetzer; Ana Sofia Ferreira Braga da Costa; Martin Kronenbürger; Jörg B Schulz; Sandra Röske; Annika Spottke; Ullrich Wüllner; Thomas Klockgether; Alexander Storch; Christine Schneider; Oliver Riedel; Hans-Ulrich Wittchen; Carola Seifried; Rüdiger Hilker; Nele Schmidt; Karsten Witt; Günther Deuschl; Brit Mollenhauer; Claudia Trenkwalder; Inga Liepelt-Scarfone; Susanne Gräber-Sultan; Daniela Berg; Thomas Gasser; Elke Kalbe; Maren Bodden; Wolfgang H Oertel; Richard Dodel Journal: Neuroepidemiology Date: 2011-11-04 Impact factor: 3.282
Authors: Jordi Alonso; Montserrat Ferrer; Barbara Gandek; John E Ware; Neil K Aaronson; Paola Mosconi; Niels K Rasmussen; Monika Bullinger; Shunichi Fukuhara; Stein Kaasa; Alain Leplège Journal: Qual Life Res Date: 2004-03 Impact factor: 4.147
Authors: Kristina Bettecken; Felix Bernhard; Jennifer Sartor; Markus A Hobert; Marc Hofmann; Till Gladow; Janet M T van Uem; Inga Liepelt-Scarfone; Walter Maetzler Journal: PLoS One Date: 2017-05-22 Impact factor: 3.240
Authors: Hans I V Lindgren; Peter Qvarfordt; Stefan Bergman; Anders Gottsäter Journal: Cardiovasc Intervent Radiol Date: 2018-03-08 Impact factor: 2.740
Authors: Emilio Fernández-Espejo; Fernando Rodríguez de Fonseca; Ana Luisa Gavito; Antonio Córdoba-Fernández; José Chacón; Ángel Martín de Pablos Journal: Antioxidants (Basel) Date: 2022-05-30
Authors: Pietro Crispino; Miriam Gino; Elena Barbagelata; Tiziana Ciarambino; Cecilia Politi; Immacolata Ambrosino; Rosalia Ragusa; Marina Marranzano; Antonio Biondi; Marco Vacante Journal: Int J Environ Res Public Health Date: 2020-12-29 Impact factor: 3.390